Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 plus chemotherapy in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
NL-OMON46453Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adavosertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Jan 2018; status: active, not recruiting.
02
Drugs
adavosertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON46453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46453.